Table 1.
Pain Model | Organism | Experimental Endpoints Measured/span> |
Anti Complement Agent |
Result | References |
---|---|---|---|---|---|
Opioid Pain Relief | Mice | Anti-analgesic effect | C3a | C3a reduces the analgesic effect on mice treated with opioid pain medication |
[27, 28] |
Sciatic Nerve Ligation | Rat | Mechanical Allodynia Cold Allodynia |
C5aR antagonist AcF- [OPdChaWR] |
Less mechanical and cold allodynia in mice treated with C5aR antagonist |
[38] |
C6 (−/−) rats | Mechanical Allodynia Cold Allodynia |
NA | Normal neuropathic pain phenotype, MAC not involved |
||
Sciatic Nerve Ligation | Rat | Mechanical hyperalgesia | CVF | Complement depletion reduces pain behavior | [26] |
Sciatic Nerve Ligation | Rat | Thermal Hyperalgesia Mechanical Allodynia |
Soluble Complement receptor (sCR1) |
C3 deposition seen after SCL and IgG injection, accompanied by macrophage recruitment. sCR1 Injections resulted in less TH and MA. |
[25] |
Spinal inflammatory Neuropathy Caused by Zymosan, GP120, and chronic constriction injury |
Rat | Mechanical Allodynia | sCR1 | sCR1 injection reduces mechanical allodynia. | [23] |
Sciatic Nerve Crush | Rat | Macrophage infiltration and activation |
Conmplement inhibitor: Cobra Venom Factor (CVF) |
Less macrophage infiltration in CVF-treated animals. |
[20] |
Sciatic Nerve Chronic constriction injury |
Mouse | Hyperalgesia | CVF | Mice given daily injections of CVF had less hyperalgesia. 1 CVF injection 4 days after surgery greatly reduced hyperalgesia. |
[30] |
Paw Incision | Mouse | Incisional Allodynia and Edema |
AcF-[OPdChaWR] | Daily injection of AcF-[OPdChaWR] reduces incisional edema and allodynia. |
[35] |
Paw injection | Mouse | Heat and Mechanical Hyperalgesia |
NA | C5a injection elicits both heat and mechanical hyperalgesia, while C3a injection elicits only mechanical hyperalgesia |
[45] |
Paw injection | Mouse | Heat Hyperalgesia and Mechanical Allodynia |
PMX53 (C5aR antagonist) |
Injection of PMX53 reduces both heat hyperalgesia and mechanical allodynia caused by injection of C5a |
[46] |
Paw Injection | Rat | Edema | Vinblastine | C5a -induced hypernociception reduced when neutraphils reduced by vinblastin treatment. |
[43] |
Hypernociception caused by injection of zymosan, carrageenan, LPS, and antigen. |
PMX53 | PMX53 injection reduced hypernociception. | |||
Rheumatoid Arthritis | Human | C5a | NA | C5a levels increased in rheumatoid joint fluids. Neutraphils increased in synovial fluid. |
[53] |
Sickle Cell Anemia | Human | Pain, C3a, C3, Bb, C4d, | NA | Measured complement levels in patients suffering severe painful episodes vs. base levels. Complement activation was higher during painful episodes. |
[24] |
C5a Injection into hindpaw |
Rat | Nociception | Hydroxyurea | C5a is a chemotactic peptide, and injection into hindpaw of rats induces hyperalgesia. In addition, PML supernatant also causes hyperalgesia. When PMLs reduced by hydroxyurea treatment, hyperalgesia reduced. |
[33] |
anti-ganglioside GD2 antibody-induced pain |
Rat | Hindpaw allodynia | Non complement-fixing antibody GD2 antibody |
Mice treated with mutant antibody with reduced CDC activity had faster resolving allodynia than those injected with "normal" antibody. C6 knockout mice had reduced allodynia, while C5aR antagonist eliminated allodynia. |
[47] |
C5a receptor knockout | Mouse | Pain, edema | C5aR knockout vs. normal. |
In C5aR−/− mice, thermal nociceptive pain reduced for 4 days post-incision, while mechanical sensitivity reduced only after 48 hrs. C5aR−/− showed little edema, while wt mice showed normal edema. |
[37] |
Hematuria/Groin Pain | Human | C3b | NA | Patients with loin pain and Haematuria had C3b deposition on arteriolar walls. |
[16] |
Spinal Cord Injury | Rat | Macrophages | Vaccinia Virus Complement Control Protein (VCP) |
VCP injection following spinal cord injury inhibits macrophage infiltration and improves hind limb function. |
[17] |
CFA and C5a injection | Mice | Threshold of pain | PMX53, knockout mice | Showed that pain is mediated by activation of TRPV1 ion channels. NGF is one activator of TRPV1. |
[49] |
Inflammatory and neuropathic pain |
Mice | Hyperalgesia | DF2593A | Showed injection of mice with DF2593A reduces inflammatory and neuropathic pain |
[52] |